Literature DB >> 16303110

Bone health and systemic lupus erythematosus.

Chin Lee1, Rosalind Ramsey-Goldman.   

Abstract

Osteoporosis is a potentially preventable condition frequently encountered in patients with systemic lupus erythematosus (SLE). Bone loss in SLE is likely a multi- factorial process involving traditional osteoporosis risk factors along with lupus-related factors. Recognizing potential contributors to bone loss in patients with SLE may allow earlier detection of osteoporosis, optimize bone health, and minimize future fracture risk. This paper discusses recent epidemiologic information related to osteoporosis and fractures in SLE, and highlights relevant developments regarding evaluation and treatment of patients at risk for bone loss.

Entities:  

Mesh：

Year:  2005        PMID： 16303110     DOI： 10.1007/s11926-005-0056-1

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


  30 in total

1.  Osteoporosis in murine systemic lupus erythematosus--a laboratory model.

Authors:  D Schapira; A Kabala; B Raz; E Israeli
Journal:  Lupus       Date:  2001       Impact factor: 2.911

2.  Osteopenia in young hypogonadal women with systemic lupus erythematosus receiving chronic steroid therapy: a randomized controlled trial comparing calcitriol and hormonal replacement therapy.

Authors:  A W Kung; T M Chan; C S Lau; R W Wong; S S Yeung
Journal:  Rheumatology (Oxford)       Date:  1999-12       Impact factor: 7.580

Review 3.  Osteoporosis in systemic lupus erythematosus: prevention and treatment.

Authors:  D Sen; R W Keen
Journal:  Lupus       Date:  2001       Impact factor: 2.911

4.  Osteoporosis screening in systemic lupus erythematosus: impact of disease duration and organ damage.

Authors:  A Becker; R Fischer; W A Scherbaum; M Schneider
Journal:  Lupus       Date:  2001       Impact factor: 2.911

5.  Past use of oral contraceptives and the risk of developing systemic lupus erythematosus.

Authors:  J Sanchez-Guerrero; E W Karlson; M H Liang; D J Hunter; F E Speizer; G A Colditz
Journal:  Arthritis Rheum       Date:  1997-05

6.  Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine.

Authors:  D Jardinet; C Lefèbvre; G Depresseux; M Lambert; J P Devogelaer; F A Houssiau
Journal:  Rheumatology (Oxford)       Date:  2000-04       Impact factor: 7.580

7.  Bone mineral density, biochemical markers of bone turnover, and hormonal status in men with systemic lupus erythematosus.

Authors:  H P Bhattoa; E Kiss; P Bettembuk; A Balogh
Journal:  Rheumatol Int       Date:  2001-11       Impact factor: 2.631

8.  The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial.

Authors:  H P Bhattoa; P Bettembuk; A Balogh; G Szegedi; E Kiss
Journal:  Osteoporos Int       Date:  2003-12-16       Impact factor: 4.507

9.  Bone mineral density changes in women with systemic lupus erythematosus.

Authors:  M Boyanov; R Robeva; P Popivanov
Journal:  Clin Rheumatol       Date:  2003-10       Impact factor: 2.980

10.  Loss of trabecular bone mineral density in systemic lupus erythematosus.

Authors:  A A Kalla; A B Fataar; S J Jessop; L Bewerunge
Journal:  Arthritis Rheum       Date:  1993-12
View more
  1 in total

1.  Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients.

Authors:  Diana Carmona-Fernandes; Maria José Santos; Inês Pedro Perpétuo; João Eurico Fonseca; Helena Canhão
Journal:  Arthritis Res Ther       Date:  2011-10-25       Impact factor: 5.156
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.